Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Eligible participants will be those diagnosed with estrogen receptor (ER)-negative \[Immunohistochemistry (IHC) ER positive \<1% ) , progesterone receptor (PR) negative(IHC PR positive \<1% ) , and human epidermal growth factor receptor 2 (HER2)-negative \[IHC 0 or +; or IHC ++, Fluorescence in situ hybridization (FISH) -\], LAR subtype with PAM pathway mutation locally recurrent inoperable or metastatic breast cancer, who have received no prior chemotherapy, targeted therapy or other treatments. The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone) either alone or in combination with everolimus. This study aims to see if everolimus plus chemotherapy allows patients to live longer without the cancer getting worse, or simply to live longer, compared to patients receiving investigator's choice of chemotherapy. This study is also looking to see how the treatment and the cancer affects patients' quality of life.